Skip to main content

Table 3 Visual acuity in patients with neovascular age-related macular degeneration without treatment in daily practice, or after PDT, bevacizumab or ranibizumab in daily practice and in patients from clinical trials

From: A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration

Regimen

VA Change (LogMAR) at 12 Months

Literature Reference

From Baseline

Versus Control Group

This Study

Literature

This Studya

Literature

No Treatment

0.54

0.2 to 0.4

–

–

[2, 4,5,6]

PDT

0.48

0.2 to 0.3

−0.06

−0.14

[2, 5,6,7]

Bevacizumab

0.09

− 0.1 to −0.16

−0.45

−0.33b

[8,9,10]

Ranibizumab

0.07

−0.1 to −0.2

−0.47

−0.35 to −0.41

[4, 7, 8, 10]

 PIER study

 

0.04

  

[11]

 SAILOR study

 

−0.04

  

[12]

Anti-VEGF outcome studies

 

−0.1 to −0.02

  

[13,14,15,16,17,18,19,20,21,22,23,24,25,26]

  1. Note: a negative LogMAR change indicates an improvement in visual acuity
  2. LogMAR Logarithm of the minimal angle of resolution, PDT Verteporfin photodynamic therapy, VA Visual acuity
  3. a compared to the no-treatment cohort
  4. b compared to ‘standard care’ in the ABC trial
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us